Study study type PathologyT1T0Patientssample sizesROB Results

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus lapatinib plus capecitabine
trastuzumab emtansine
EMILIA, 2012
  NCT00829166
RCTla/mBC - HER2 positive - 2nd Line (L2)trastuzumab emtansinelapatinib plus capecitabinepatients with HER2-positive unresectable, locally advanced or metastatic breast cancer, who had previously been treated with trastuzumab and a taxane.495 / 496some concern
conclusif
  • demonstrated 32 % decrease in deaths (OS) (PE)
  • demonstrated 35 % decrease in progression or deaths (PFS) (PE)
  • suggested 25 % decrease in deaths (OS) (extension)
  • demonstrated 73 % increase in objective responses (ORR) (PE)